Sandrine Hirschi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Sandrine Hirschi has a total of 252 co-authors. Here are the top co-authors by number of shared publications:
- Romain Kessler
Pneumology Department, Lung Transplant Program, NHC, Strasbourg University Hospital, Strasbourg, France
6 shared publications - Sylvain Marchand Adam
University of Tours, Tours, France
5 shared publications - Benjamin Renaud-Picard
Department of Pneumology, Strasbourg Lung Transplant Program, Strasbourg University Hospital, Strasbourg, France
3 shared publications - Bruno Crestani
Service de Pneumologie, Allergologie et Transplantation, AP-HP, Hôpital Bichat Claude Bernard, Paris, France
3 shared publications - Hilario Nunes
Assistance Publique-Hôpitaux de Paris, Hôpital Avicenne, Service de Pneumologie
3 shared publications - Lidwine Wemeau
Service de Pneumologie et Immuno-Allergologie, Centre de référence constitutif des maladies pulmonaires rares (site constitutif), CHU de Lille, Lille, France
3 shared publications
Latest Publications
- Open Access
- 21 August 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (1) , 37-46
Diagnostic significance of intragraft donor–specific anti-HLA antibodies in pulmonary antibody–mediated rejection
- 21 August 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 45 (1) , 37-46
Open AccessDiagnostic significance of intragraft donor–specific anti-HLA antibodies in pulmonary antibody–mediated rejection
- Open Access
- 4 April 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 63 (5) , 2301809
High risk of lung cancer in surfactant-related gene variant carriers
Background: Several rare surfactant-related gene (SRG) variants associated with interstitial lung disease are suspected to be associated with lung cancer, but data are missing. We aimed to study the epidemiology and phenotype of lung cancer in an international cohort of SRG variant carriers.Methods: We conducted a cross-sectional study of all adults with SRG variants in the OrphaLung network and compared lung cancer risk with telomere-related gene (TRG) variant carriers.Results: We identified 99 SRG adult variant carriers (SFTPA1(n=18),SFTPA2(n=31),SFTPC(n=24),ABCA3(n=14) andNKX2-1(n=12)), including 20 (20.2%) with lung cancer (SFTPA1(n=7),SFTPA2(n=8),SFTPC(n=3),NKX2-1(n=2) andABCA3(n=0)). Among SRG variant carriers, the odds of lung cancer was associated with age (OR 1.04, 95% CI 1.01–1.08), smoking (OR 20.7, 95% CI 6.60–76.2) andSFTPA1/SFTPA2variants (OR 3.97, 95% CI 1.39–13.2). Adenocarcinoma was the only histological type reported, with programmed death ligand-1 expression ≥1% in tumour cells in three samples. Cancer staging was localised (I/II) in eight (40%) individuals, locally advanced (III) in two (10%) and metastatic (IV) in 10 (50%). We found no somatic variant eligible for targeted therapy. Seven cancers were surgically removed, 10 received systemic therapy, and three received the best supportive care according to their stage and performance status. The median overall survival was 24 months, with stage I/II cancers showing better survival. We identified 233 TRG variant carriers. The comparative risk (subdistribution hazard ratio) for lung cancer in SRG patientsversusTRG patients was 18.1 (95% CI 7.1–44.7).Conclusions: The high risk of lung cancer among SRG variant carriers suggests specific screening and diagnostic and therapeutic challenges. The benefit of regular computed tomography scan follow-up should be evaluated.
- 4 April 2024
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 63 (5) , 2301809
Open AccessHigh risk of lung cancer in surfactant-related gene variant carriers
Background: Several rare surfactant-related gene (SRG) variants associated with interstitial lung disease are suspected to be associated with lung cancer, but data are missing. We aimed to study the epidemiology and phenotype of lung cancer in an international cohort of SRG variant carriers.Methods: We conducted a cross-sectional study of all adults with SRG variants in the OrphaLung network and compared lung cancer risk with telomere-related gene (TRG) variant carriers.Results: We identified 99 SRG adult variant carriers (SFTPA1(n=18),SFTPA2(n=31),SFTPC(n=24),ABCA3(n=14) andNKX2-1(n=12)), including 20 (20.2%) with lung cancer (SFTPA1(n=7),SFTPA2(n=8),SFTPC(n=3),NKX2-1(n=2) andABCA3(n=0)). Among SRG variant carriers, the odds of lung cancer was associated with age (OR 1.04, 95% CI 1.01–1.08), smoking (OR 20.7, 95% CI 6.60–76.2) andSFTPA1/SFTPA2variants (OR 3.97, 95% CI 1.39–13.2). Adenocarcinoma was the only histological type reported, with programmed death ligand-1 expression ≥1% in tumour cells in three samples. Cancer staging was localised (I/II) in eight (40%) individuals, locally advanced (III) in two (10%) and metastatic (IV) in 10 (50%). We found no somatic variant eligible for targeted therapy. Seven cancers were surgically removed, 10 received systemic therapy, and three received the best supportive care according to their stage and performance status. The median overall survival was 24 months, with stage I/II cancers showing better survival. We identified 233 TRG variant carriers. The comparative risk (subdistribution hazard ratio) for lung cancer in SRG patientsversusTRG patients was 18.1 (95% CI 7.1–44.7).Conclusions: The high risk of lung cancer among SRG variant carriers suggests specific screening and diagnostic and therapeutic challenges. The benefit of regular computed tomography scan follow-up should be evaluated.
- Open Access
- 6 October 2023
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (3) , 403-413
Assessing the role of phosphorylated S6 ribosomal protein in the pathological diagnosis of pulmonary antibody-mediated rejection
- 6 October 2023
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 43 (3) , 403-413
Open AccessAssessing the role of phosphorylated S6 ribosomal protein in the pathological diagnosis of pulmonary antibody-mediated rejection
- 10 November 2021
- Published by Springer Nature in Advances in Therapy
- Vol. 39 (1) , 405-420
Treatment of Idiopathic Pulmonary Fibrosis with Capsule or Tablet Formulations of Pirfenidone in the Real-Life French RaDiCo-ILD Cohort
Introduction Pirfenidone, an antifibrotic medication for idiopathic pulmonary fibrosis (IPF), is now available in France in two formulations: tablets since April 2018, and the initial capsules form. We conducted a cohort study to describe tolerance and acceptability of capsules and/or tablets of pirfenidone in patients with IPF. Methods This study was nested within the French, non-randomized, multicenter RaDiCo-ILD (Rare Disease Cohort–Interstitial Lung Diseases). Included patients with IPF received at least one dose of pirfenidone tablets or capsules from July 2017 to June 2019 in three populations: the inclusion population (patients treated at least once with pirfenidone during the study period, n = 288); the potential switch population (patients treated with pirfenidone during the switch period starting April 2018, n = 256); the newly treated population (patients who initiated pirfenidone during the study period, n = 162). Each of those last two populations included three subgroups (tablets, capsules, and substitution). Results In 288 patients treated, 162 newly initiated pirfenidone during the study period: there were no meaningful differences in the baseline characteristics with the 256 patients treated during the potential switch period. In the newly treated population, 30.3% started pirfenidone treatment with tablet formulation. In the potential switch population, 44.9% of patients shifted from capsule to tablet. Half of the patients shifted to tablet formulation within the first 10 months. The mean treatment duration was 21.5 months with a mean dose of 2106.7 mg/day; 46.5% of patients discontinued treatment, mainly because of adverse events. There were fewer discontinuations in the tablets and substitution subgroups than in the capsules-only subgroup. The most reported adverse event was skin rash (11.5%). No new adverse event was identified. Conclusions This real-life cohort assessing the characteristics of the prescription of pirfenidone tablets and capsules suggests a good acceptability of the tablet formulation by patients with IPF. Trial Registration Clinical trial registered with www.clinicaltrials.gov (NCT04238871).
- 10 November 2021
- Published by Springer Nature in Advances in Therapy
- Vol. 39 (1) , 405-420
Treatment of Idiopathic Pulmonary Fibrosis with Capsule or Tablet Formulations of Pirfenidone in the Real-Life French RaDiCo-ILD Cohort
Introduction Pirfenidone, an antifibrotic medication for idiopathic pulmonary fibrosis (IPF), is now available in France in two formulations: tablets since April 2018, and the initial capsules form. We conducted a cohort study to describe tolerance and acceptability of capsules and/or tablets of pirfenidone in patients with IPF. Methods This study was nested within the French, non-randomized, multicenter RaDiCo-ILD (Rare Disease Cohort–Interstitial Lung Diseases). Included patients with IPF received at least one dose of pirfenidone tablets or capsules from July 2017 to June 2019 in three populations: the inclusion population (patients treated at least once with pirfenidone during the study period, n = 288); the potential switch population (patients treated with pirfenidone during the switch period starting April 2018, n = 256); the newly treated population (patients who initiated pirfenidone during the study period, n = 162). Each of those last two populations included three subgroups (tablets, capsules, and substitution). Results In 288 patients treated, 162 newly initiated pirfenidone during the study period: there were no meaningful differences in the baseline characteristics with the 256 patients treated during the potential switch period. In the newly treated population, 30.3% started pirfenidone treatment with tablet formulation. In the potential switch population, 44.9% of patients shifted from capsule to tablet. Half of the patients shifted to tablet formulation within the first 10 months. The mean treatment duration was 21.5 months with a mean dose of 2106.7 mg/day; 46.5% of patients discontinued treatment, mainly because of adverse events. There were fewer discontinuations in the tablets and substitution subgroups than in the capsules-only subgroup. The most reported adverse event was skin rash (11.5%). No new adverse event was identified. Conclusions This real-life cohort assessing the characteristics of the prescription of pirfenidone tablets and capsules suggests a good acceptability of the tablet formulation by patients with IPF. Trial Registration Clinical trial registered with www.clinicaltrials.gov (NCT04238871).
- 1 July 2021
- Published by Elsevier in Respiratory Medicine
- Vol. 183, 106415
Low income and outcome in idiopathic pulmonary fibrosis: An association to uncover
- 1 July 2021
- Published by Elsevier in Respiratory Medicine
- Vol. 183, 106415
Low income and outcome in idiopathic pulmonary fibrosis: An association to uncover
- 1 November 2020
- Published by Elsevier in Transplantation Proceedings
- Vol. 52 (9) , 2715-2718
Bilateral Acute Cardioembolic Limb Ischemia After Coronavirus Disease 2019 Pneumonia in a Lung Transplant Recipient: A Case Report
- 1 November 2020
- Published by Elsevier in Transplantation Proceedings
- Vol. 52 (9) , 2715-2718
Bilateral Acute Cardioembolic Limb Ischemia After Coronavirus Disease 2019 Pneumonia in a Lung Transplant Recipient: A Case Report
- 1 January 2020
- Published by Elsevier in Revue des Maladies Respiratoires Actualités
- Vol. 12 (1) , 233-234
Données démographiques et caractéristiques au moment du diagnostic des 847 patients atteints de fibrose pulmonaire idiopathique inclus dans la cohorte Radico-PID
- 1 January 2020
- Published by Elsevier in Revue des Maladies Respiratoires Actualités
- Vol. 12 (1) , 233-234
Données démographiques et caractéristiques au moment du diagnostic des 847 patients atteints de fibrose pulmonaire idiopathique inclus dans la cohorte Radico-PID
- 1 December 2019
- Published by Elsevier in Transplantation Proceedings
- Vol. 51 (10) , 3375-3384
Organized Management of Diabetes Mellitus in Lung Transplantation: Study of Glycemic Control and Patient Survival in a Single Center
- 1 December 2019
- Published by Elsevier in Transplantation Proceedings
- Vol. 51 (10) , 3375-3384
Organized Management of Diabetes Mellitus in Lung Transplantation: Study of Glycemic Control and Patient Survival in a Single Center